Daniel Smith
Director, Regulatory StrategyOver 20 years in the industry; from a lab-based non-clinical pathology start, to quality management, safety management and regulatory affairs. Experience across ATMPs to consumer healthcare for small biotechs through to blue chip pharma, in senior management, leadership and consulting positions. Until recently working at the forefront of microbiome science, exploring immuno-oncological, neurodegenerative CNS and gastrointestinal indications. Now working on orphan drug development in the EU and US, as well as a number of clinical programmes in support of similar developments.